Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan A. García-Guzmán has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Antonio Abad-García

    Academia de Fisiología, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomas, Alc. Miguel Hidalgo, Mexico City 11340, Mexico

    1 shared publication
  • David Centurión

    Departamento de Farmacobiología, Cinvestav-Coapa, Czda. de los Tenorios 235, Col. Granjas-Coapa, Del. Tlalpan, C.P. 14330 México City, Mexico

    1 shared publication
  • Iris Yuritzi Torres-Deviana

    Academia de Fisiología, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomas, Alc. Miguel Hidalgo, Mexico City 11340, Mexico

    1 shared publication
  • José Guadalupe Trujillo Ferrara

    Laboratorio de Bioquímica, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomas, Alc. Miguel Hidalgo, Mexico City 11340, Mexico

    1 shared publication
  • Karen A. Cruz-Aguayo

    Academia de Fisiología, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomas, Alc. Miguel Hidalgo, Mexico City 11340, Mexico

    1 shared publication
  • Maricarmen Hernández-Rodríguez

    Academia de Fisiología, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomas, Alc. Miguel Hidalgo, Mexico City 11340, Mexico

    1 shared publication

Latest Publications

  • Open Access

    Aryl-Boroxazolidones with Low In Vitro Neurotoxicity and Alleviative Effects on MPTP-Induced Parkinsonism in Mice

    by Antonio Abad-García, Martiniano Bello, Maricarmen Hernández-Rodríguez, Iris Yuritzi Torres-Deviana, Juan A. García-Guzmán, Karen A. Cruz-Aguayo, Mónica Barrón-González, José G. Trujillo-Ferrara, David Centurion, Marvin A. Soriano-Ursúa

    Parkinson’s disease (PD) is one of the most prevalent and extensively studied neurodegenerative conditions. One of its most challenging clinical manifestations is the emergence of dyskinesias, characterized by involuntary movements that significantly impair patients’ quality of life. Meanwhile, boron, as a trace element, and boron-containing compounds have emerged as active modulators of neurotransmitter systems. To evaluate the effect of aryl-boroxazolidones on parkinsonism, the in vitro neurotoxicity of three boroxazolidones was assessed, along with the effects of two of them in mice with parkinsonism induced by MPTP administration. Two novel compounds demonstrated a limitation of parkinsonism, whereas risperidone reduced the beneficial effect of the tested boroxazolidones. The three boroxazolidones did not induce toxicity in neurons or glial cells at concentrations up to 100 µM. In silico analyses support the ability of BCC to act as ligands of dopamine and serotonin receptors. Taken together, these results suggest that the tested boroxazolidones are promising candidate agents, warranting further exploration for the treatment of PD.